Sébastien Aguettant has been the president of the Delpharm group since 2024 while he was already managing director since 2004 and had held both positions since 2010. Delpharm is one of the European leaders in pharmaceutical subcontracting. It is originally a subsidiary of the Aguettant group, a pharmaceutical laboratory specializing in injectable products for the hospital market and founded more than a century ago in Lyon, France.

He successively held the positions of management assistant at the Delmas laboratory from 1996 to 1998, sales director of the Delpharm group from 1999 to 2001 and site manager for the Delpharm Brétigny site from 2001 to 2004.

He was a director of the LEEM from 2004 to 2020 and is the founding president of the SPIS, the Professional Union of Industrial Health Subcontractors, which became CDMO-France. Sébastien Aguettant holds a DEA in taxation from the University Panthéon Sorbonne, a master’s degree in business law from Paris Assas and is also a graduate of the ISC Paris.

He has been chairman of the supervisory board of the Aguettant group since 2008.

Delpharm is a global leader in the development and contract manufacturing of medicines for pharmaceutical companies. The company manufactures annually more than one billion units in its production sites (11 in France, 2 in Italy, 2 in Canada, 2 in the Netherlands and 1 in Poland) supplying the majority of dosage forms available on the market: tablets, injectable vials / ampoules / pre-filled syringesfilled, lyophilization, suspensions, solutions, ointments and soft gels. In addition, Delpharm has a sterile development centre in the Netherlands. The company employs more than 6,500 people and achieved a turnover of 1.1 billion euros in 2023.